Aikewei IPO: Sustainability of Core Product Sales in Question; Fund-raising Projects May Already Be Under Construction

Jiangsu Aikewei Technology Co., Ltd. (hereinafter referred to as 'Aikewei') had its IPO application for the Beijing Stock Exchange accepted on December 26, 2024, officially launching its push toward listing. Aikewei is a high-tech enterprise specializing in the research, development, production, and sales of fine chemical products based on oxime compounds. The company consistently expands its product portfolio around the 'oxime+' strategy. Its current core products include oxime-based silanes (methyltris(butylketoximo)silane and vinyltris(butylketoximo)silane), hydroxylamine salts (hydroxylamine sulfate and hydroxylamine hydrochloride), and basic oxime compounds (acetaldoxime and acetone oxime). Collectively, these constitute Aikewei’s primary line of fine chemical products. Oximes—organic compounds formed when aldehydes or ketones react with hydroxylamine—are widely applied across solar photovoltaics, new-energy lithium batteries, electronics and electrical appliances, construction materials, and other sectors. From 2021 through June 2024 (hereinafter referred to as the 'reporting period'), Aikewei’s operating revenues amounted to RMB 610.86 million, RMB 655.53 million, RMB 683.58 million, and RMB 425.53 million, respectively; corresponding non-recurring net profits were RMB 155.52 million, RMB 124.72 million, RMB 137.36 million, and RMB 120.17 million. Year-on-year revenue growth stood at 7.31% in 2022 and 4.28% in 2023; non-recurring net profit growth was −19.81% in 2022 and +10.13% in 2023. Notably, Aikewei’s 2023 profit growth significantly outpaced its revenue growth—and performance accelerated further in the first half of 2024. According to its prospectus, Aikewei’s revenue is primarily derived from methyltris(butylketoximo)silane, vinyltris(butylketoximo)silane, hydroxylamine hydrochloride, hydroxylamine sulfate, and acetaldoxime—with acetaldoxime showing particularly rapid sales growth. During the reporting period, acetaldoxime accounted for 9.32%, 18.84%, 26.73%, and 40.27% of the company’s main business revenue, respectively; its unit price per ton was RMB 21,300, RMB 19,200, RMB 19,400, and RMB 21,900, respectively. In the first half of 2024, the unit price rose 12.81% year-on-year, reflecting an initial decline followed by a rebound. By contrast, unit prices for Aikewei’s other major products either declined or rose only marginally: methyltris(butylketoximo)silane fell 3.81% year-on-year; vinyltris(butylketoximo)silane dropped 2.43%; hydroxylamine hydrochloride rose 1.26% (though it had fallen 13.73% in 2023); and hydroxylamine sulfate dipped 0.60%. In response, Aikewei’s prospectus states: 'During the reporting period, acetaldoxime revenue surged dramatically. Since commercial production began in April 2021, Aikewei has become the leading supplier of 65%-concentration acetaldoxime in the market. Its stable product quality has earned strong recognition from downstream customers, enabling continuous expansion of production and sales volumes. Starting in November 2023, peer companies undertook technical upgrades to their acetaldoxime production facilities, reducing output and overall market supply—further boosting demand for Aikewei’s acetaldoxime.'

Moderna Q3 Earnings: Full-Year Revenue Growth Forecast Raised to 15%–25%; Melanoma Vaccine Expected to File for Approval This Year

Investor Conference Call Transcript On November 6, 2026 (Eastern Time), Moderna released its third-quarter 2026 financial results and held an investor conference call, delivering both a return to quarterly profitability and its first positive Phase 3 clinical data in oncology. After two years marked by declining respiratory vaccine revenues and a streamlined R&D pipeline, the company reported total revenue of $1.313 billion (up 29% year-on-year) and GAAP net income of $162 million for Q3. Management accordingly raised its full-year 2026 total revenue growth guidance from 'up to 10%' to '15%–25%', while cutting its full-year R&D expense budget by an additional $200 million. The pivotal clinical breakthrough came from intismeran autogene (development code mRNA-4157/V940, hereinafter 'intismeran'), an individualized neoantigen therapy co-developed with Merck & Co. under a 50:50 partnership. At the recent European Society for Medical Oncology (ESMO) Annual Congress Presidential Symposium, the randomized, double-blind Phase 3 INTerpath-001 trial reported that intismeran combined with pembrolizumab reduced the risk of recurrence or death by 42% versus pembrolizumab monotherapy in the adjuvant treatment of high-risk resectable Stage IIB–IV melanoma. Among the 1,137-patient intent-to-treat (ITT) population, the risk reduction was 42%; among the modified ITT (mITT) population—defined as patients who received at least one dose of vaccine or placebo (n = 1,091)—the risk reduction widened to 49%. The company confirmed it is collaborating with Merck to prepare the Biologics License Application (BLA) and plans to submit it to the U.S. Food and Drug Administration (FDA) before year-end 2026, targeting approval in 2027. I. Commercial and Financial Turnaround: Quarterly Net Profit of $162 Million; Year-End Cash Balance Expected to Reach $8.1–$8.3 Billion Of Q3’s $1.313 billion in total revenue, product net sales totaled $1.273 billion (up 31% year-on-year from $973 million), while other income—including international collaborations, licensing, and capacity reservation services—amounted to $40 million. By product, the two COVID-19 vaccines, Spikevax and mNEXSPIKE, collectively contributed $1.244 billion (up from $971 million year-on-year); the respiratory syncytial virus (RSV) vaccine mRESVIA contributed $29 million (up from $2 million year-on-year); and the seasonal influenza vaccine mFLUSIVA (mRNA-1010), which received FDA approval in August 2026, launched limited commercialization in September due to its late approval relative to annual procurement contracting cycles—resulting in negligible revenue for the quarter. By geography, U.S. revenue totaled $780 million ($771 million in product net sales plus $9 million in other income), representing ~60% of total revenue—driven primarily by rapid uptake of the next-generation refrigerated-stable COVID-19 vaccine mNEXSPIKE (mRNA-1283) across retail pharmacies and healthcare institutions. International revenue totaled $533 million—including $314 million in product net sales in Europe, $188 million in product net sales in other international markets, and $31 million in other income (e.g., international collaborations). Europe’s product net sales surged dramatically compared to $16 million year-on-year—accounting for ~40% of total revenue.

Ecovyst Inc Raises 2026 EBITDA Guidance Amid Strong Sulfuric Acid Demand

4 days ago

Ecovyst Inc raised its full-year 2026 adjusted EBITDA guidance to $208-$212 million, driven by strong sulfuric acid demand. Despite higher sulfur costs, the company remains bullish on fundamentals following the Calabrian acquisition integration.

Yahoo Finance UK

2026-01-02

Technip completes acquisition of Ecovyst advanced materials, catalysts business

2026-02-26

Ecovyst beats estimates on stronger sulfuric acid volumes

2026-03-04

Symrise Expects Further Organic Sales Growth Despite 2025 Earnings Decline

2026-04-03

OCP reports strong revenue growth amid robust global phosphate demand

2026-04-04

Ecovyst Inc Reports Q4 Earnings Beat, Highlights Refinery & Sulfuric Acid Growth